Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Previous Page Next Page

Safety

Adult patients

The most common adverse reactions (occurring in ≥20% of the patients) observed in the three trials that supported the registration of entrectinib were: fatigue, constipation, dysgeusia, oedema, dizziness, diarrhoea, nausea, dysaesthesia, dyspnoea, anaemia, increased weight, increased blood creatinine, pain, cognitive disorders, vomiting, cough, and pyrexia. The most frequent serious adverse reactions (≥2%) were lung infection (5.2%), dyspnoea (4.6%), cognitive impairment (3.8%), and pleural effusion (3.0%) and fractures (2.4%). Permanent discontinuation due to an adverse reaction occurred in 4.6% of patients [1].


Paediatric patients

The overall safety profile of entrectinib in the paediatric population is similar to the safety profile described for adults [1].


References

  1. ROZLYTREK (entrectinib), EMA Summary of medicinal Product Characteristics. 2022.
  2. Krzakowski MJ, Lu S, Cousin S, Smit EF, Springfeld C, Goto K, Garrido P, Chung CH, Lin JJ, Bray VJ, Pitcher B, Zeuner H, Patel S, Bordogna W, and Gelderblom H. Updated analysis of the efficacy and safety of entrectinib in patients (pts) with locally advanced/metastatic NTRK fusion-positive (NTRK-fp) solid tumors. Journal of Clinical Oncology 2022; 40:16_suppl, 3099-3099

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.